Abstract
22 patients infected with fluoroquinolone-resistant Mycobacterium tuberculosis in New York City were identified between January, 1991, and November, 1993. In 16 patients resistance arose as a result of inadequate or inappropriate treatment. 6 patients had primary infection with fluoroquinolone-resistant organisms; 5 acquired the organisms nosocomially. Seven distinct patterns of restriction-fragment length polymorphism were identified in isolates from 21 patients. Fluoroquinolones should be restricted to patients with multidrug-resistant disease or intolerance to other antituberculosis drugs. All patients with multidrug-resistant tuberculosis should be on directly observed therapy.
Publication types
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
AIDS-Related Opportunistic Infections / drug therapy
-
AIDS-Related Opportunistic Infections / epidemiology
-
AIDS-Related Opportunistic Infections / microbiology
-
Adult
-
Anti-Infective Agents / pharmacology*
-
Antitubercular Agents / therapeutic use
-
Drug Therapy, Combination
-
Female
-
Fluoroquinolones
-
Humans
-
Male
-
Middle Aged
-
Mutation
-
Mycobacterium tuberculosis / classification
-
Mycobacterium tuberculosis / drug effects
-
Mycobacterium tuberculosis / genetics
-
Mycobacterium tuberculosis / isolation & purification
-
New York City / epidemiology
-
Polymorphism, Restriction Fragment Length
-
Tuberculosis, Multidrug-Resistant / drug therapy
-
Tuberculosis, Multidrug-Resistant / epidemiology*
-
Tuberculosis, Multidrug-Resistant / microbiology
-
Tuberculosis, Pulmonary / drug therapy
-
Tuberculosis, Pulmonary / epidemiology*
-
Tuberculosis, Pulmonary / microbiology
Substances
-
Anti-Infective Agents
-
Antitubercular Agents
-
Fluoroquinolones